Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms.

Lisa Xingguang LeePing ZhouCindy VargaTeresa FogarenKatelynn HoXun MaMelissa WarnerDenis ToskicAdin KugelmassRaymond L Comenzo

Published in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2019)

Keyphrases

multiple myeloma
acute lymphoblastic leukemia
acute myeloid leukemia
hodgkin lymphoma
binding protein
drug induced